Collection
Immune checkpoint inhibitors in cancer treatment
- Submission status
- Closed
The advent and validation of immune checkpoint inhibitors targeting the T cell receptors PD1 and CTLA have been 'game changers' in clinical cancer therapy. Initially approved for melanoma, lung cancer, and kidney cancer these therapies have now gained substantial inroads in a diversity of tumor types as first or second-line therapy and promise to extend the lives of millions of more cancer patients. However, there is critical ongoing research attempting to optimize the therapeutic utility of these agents. Current investigations include analysis of tumor molecular profiles most apt to respond to specific checkpoint immunotherapy regimens, optimal timing of treatment and combination with chemotherapy, radiation, and molecularly targeted anti-cancer agents, and the potential to enhance responsiveness of checkpoint inhibition with concurrent use of novel therapies targeting innate or adaptive immunity. Research in all these areas has exploded at both the clinical and experimental levels. As such, these burgeoning reports comprise a valued addition and are a new cornerstone in Springer Nature's topical online collections in cancer research.
Articles (37 in this collection)
-
-
The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma
Authors (first, second and last of 5)
- Qing-Qing Liu
- Xiang-Xu Wang
- Hong-Mei Zhang
- Content type: Original Paper
- Published: 25 March 2024
- Medical Oncology
- Article: 91
-
Estrogen-receptor status determines differential regulation of α1- and α2-adrenoceptor-mediated cell survival, angiogenesis, and intracellular signaling responses in breast cancer cell lines
Authors (first, second and last of 5)
- Hannah P. Priyanka
- Uday P. Pratap
- Srinivasan ThyagaRajan
- Content type: Original Paper
- Published: 25 March 2024
- Medical Oncology
- Article: 92
-
Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events
Authors (first, second and last of 7)
- Seyed Mohammadmahdi Meybodi
- Bahareh Farasati Far
- Ali Akbar Samadani
- Content type: Review Article
- Published: 15 July 2023
- Medical Oncology
- Article: 243
-
Combinatorial targeting of immune checkpoints and epigenetic regulators for hepatocellular carcinoma therapy
Authors
- Mehmet Akce
- Bassel F El-Rayes
- Narendra Wajapeyee
- Content type: Review Article
- Published: 01 March 2023
- Oncogene
- Pages: 1051 - 1057
-
PD-1/PD-L1 blockade inhibits epithelial-mesenchymal transition and improves chemotherapeutic response in breast cancer
Authors (first, second and last of 4)
- Gisha Rose Antony
- Ajeesh Babu Littleflower
- Lakshmi Subhadradevi
- Content type: Original Paper
- Published: 26 February 2023
- Medical Oncology
- Article: 108
-
Immune checkpoint inhibitor using in cases with gestational trophoblastic diseases
Authors
- Semra Paydas
- Content type: Review Article
- Published: 23 February 2023
- Medical Oncology
- Article: 106
-
Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies
Authors
- Nehad M. Ayoub
- Dalia R. Ibrahim
- Amer E. Alkhalifa
- Content type: Review Article
- Published: 19 October 2021
- Medical Oncology
- Article: 143
-
Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model
Authors (first, second and last of 10)
- Huan Zhang
- Weimin Xie
- Hua Wang
- Content type: Article
- Open Access
- Published: 24 September 2021
- Cancer Gene Therapy
- Pages: 456 - 465
-
CD8+ T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer
Authors (first, second and last of 14)
- Xingyu Chen
- Runshi Xu
- Ke Cao
- Content type: Article
- Published: 22 September 2021
- Oncogene
- Pages: 6223 - 6234
-
Tumor suppressor immune gene therapy to reverse immunotherapy resistance
Authors (first, second and last of 10)
- Sunil Chada
- Dora Wiederhold
- Robert E. Sobol
- Content type: Article
- Open Access
- Published: 05 August 2021
- Cancer Gene Therapy
- Pages: 825 - 834
-
Computational study on novel natural inhibitors targeting BCL2
Authors (first, second and last of 11)
- Xiaye Lv
- Yuting Jiang
- Zhenghe Chen
- Content type: Original Paper
- Open Access
- Published: 14 July 2021
- Medical Oncology
- Article: 94
-
Dexamethasone suppresses immune evasion by inducing GR/STAT3 mediated downregulation of PD-L1 and IDO1 pathways
Authors (first, second and last of 14)
- Zhen Xiang
- Zhijun Zhou
- Yingyan Yu
- Content type: Article
- Open Access
- Published: 26 June 2021
- Oncogene
- Pages: 5002 - 5012
-
CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy
Authors (first, second and last of 13)
- Zhifang Zhang
- Annie Yang
- Yanghee Woo
- Content type: Article
- Published: 09 June 2021
- Cancer Gene Therapy
- Pages: 722 - 733
-
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
Authors (first, second and last of 4)
- Naval Daver
- Ahmad S. Alotaibi
- Marion Subklewe
- Content type: Review Article
- Open Access
- Published: 05 May 2021
- Leukemia
- Pages: 1843 - 1863
-
PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer
Authors (first, second and last of 4)
- Devashish Desai
- Pushti Khandwala
- Rashmika Potdar
- Content type: Review Article
- Published: 23 April 2021
- Medical Oncology
- Article: 61
-
Cancer immunotherapies revisited: state of the art of conventional treatments and next-generation nanomedicines
Authors (first, second and last of 4)
- Coral GarcÃa-Fernández
- Anna Saz
- Salvador Borrós
- Content type: Review Article
- Published: 09 April 2021
- Cancer Gene Therapy
- Pages: 935 - 946
-
Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape
Authors
- Ya-Ching Hsieh
- Kristina Kirschner
- Mhairi Copland
- Content type: Review Article
- Open Access
- Published: 08 April 2021
- Leukemia
- Pages: 1229 - 1242
-
Recent advances in immune therapies for gastric cancer
Authors
- Matthew J. Olnes
- Holly A. Martinson
- Content type: Review Article
- Published: 04 March 2021
- Cancer Gene Therapy
- Pages: 924 - 934
-
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
Authors (first, second and last of 66)
- Reid W. Merryman
- Luca Castagna
- Carmelo Carlo-Stella
- Content type: Article
- Published: 03 March 2021
- Leukemia
- Pages: 2672 - 2683
-
Sarcoid-like reaction in cases treated by checkpoint inhibitors
Authors
- Semra Paydas
- Content type: Review Article
- Published: 18 February 2021
- Medical Oncology
- Article: 29
-
HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression
Authors (first, second and last of 11)
- Xiaolei Li
- Xiao Su
- Yufang Shi
- Content type: Article
- Open Access
- Published: 09 February 2021
- Oncogene
- Pages: 1836 - 1850
-
Nanomedicine-based cancer immunotherapy: recent trends and future perspectives
Authors (first, second and last of 11)
- Vinoth-Kumar Lakshmanan
- Shlok Jindal
- Salem Chouaib
- Content type: Review Article
- Published: 08 February 2021
- Cancer Gene Therapy
- Pages: 911 - 923
-
Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor
Authors (first, second and last of 4)
- Joseph E. Grossman
- Divya Vasudevan
- Manuel Hildago
- Content type: Editorial
- Open Access
- Published: 26 January 2021
- Oncogene
- Pages: 1393 - 1395
-
Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity
Authors (first, second and last of 5)
- Chushu Li
- Han Yao
- Jie Xu
- Content type: Article
- Published: 15 December 2020
- Oncogene
- Pages: 1128 - 1146
-
Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy
Authors (first, second and last of 5)
- Chuanhui Han
- Anli Zhang
- Yang-Xin Fu
- Content type: Review Article
- Published: 07 December 2020
- Oncogene
- Pages: 885 - 898
-
The role of natural killer cell in gastrointestinal cancer: killer or helper
Authors
- Feixue Wang
- Jennie Ka Ching Lau
- Jun Yu
- Content type: Review Article
- Open Access
- Published: 01 December 2020
- Oncogene
- Pages: 717 - 730
-
Proteasome inhibitors attenuates mitoxantrone-triggered immunogenic cell death in prostate cancer cells
Authors (first, second and last of 10)
- Wei Wei
- Haibin Li
- Changlin Li
- Content type: Original Paper
- Published: 19 November 2020
- Medical Oncology
- Article: 116
-
Immune-based therapies in the management of multiple myeloma
Authors
- Saurabh Zanwar
- Bharat Nandakumar
- Shaji Kumar
- Content type: Review Article
- Open Access
- Published: 22 August 2020
- Blood Cancer Journal
- Article: 84
-
EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma
Authors (first, second and last of 10)
- Weimei Huang
- Anqi Lin
- Jian Zhang
- Content type: Article
- Published: 06 August 2020
- Cancer Gene Therapy
- Pages: 864 - 874
-
Acute myeloid leukemia sensitivity to metabolic inhibitors: glycolysis showed to be a better therapeutic target
Authors (first, second and last of 11)
- Beatriz Lapa
- Ana Cristina Gonçalves
- Ana Bela Sarmento-Ribeiro
- Content type: Original Paper
- Published: 28 July 2020
- Medical Oncology
- Article: 72
-
p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer
Authors (first, second and last of 15)
- Jinghui Liu
- Daheng He
- Xiaoqi Liu
- Content type: Article
- Published: 23 March 2020
- Oncogene
- Pages: 3939 - 3951
-
Immune-based therapies for hepatocellular carcinoma
Authors (first, second and last of 11)
- David J. Pinato
- Nadia Guerra
- Lorenza Rimassa
- Content type: Review Article
- Open Access
- Published: 10 March 2020
- Oncogene
- Pages: 3620 - 3637
-
Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1
Authors (first, second and last of 13)
- Michael Timaner
- Ruslana Kotsofruk
- Yuval Shaked
- Content type: Article
- Open Access
- Published: 29 August 2019
- Oncogene
- Pages: 187 - 203
-
Synergistic antitumor effect on cervical cancer by rational combination of PD1 blockade and CRISPR-Cas9-mediated HPV knockout
Authors (first, second and last of 5)
- Shuai Zhen
- Jiaojiao Lu
- Xu Li
- Content type: Article
- Published: 27 August 2019
- Cancer Gene Therapy
- Pages: 168 - 178
-
Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front
Authors
- Maria Saigi
- Juan J. Alburquerque-Bejar
- Montse Sanchez-Cespedes
- Content type: Review Article
- Published: 28 June 2019
- Oncogene
- Pages: 5921 - 5932
-
Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth
Authors (first, second and last of 9)
- Thuy Phan
- Vu H. Nguyen
- Laleh G. Melstrom
- Content type: Article
- Published: 01 March 2019
- Cancer Gene Therapy
- Pages: 235 - 245